Table 6.
Daily Profits Generated Based on Drug Use in the Different Clinic Models
| Model | Patients Seen Per Day, n | Total Cost Per Encounter | Total Cost Per Day | Revenue Per Encounter | Total Revenue Per Day | Total Profit Per Day |
|---|---|---|---|---|---|---|
| With VA assessment and DFE | ||||||
| Bevacizumab | 48 | $85.55 | $4106.24 | $284.32 | $13,647.36 | $9540.96 |
| Aflibercept | $1787.58 | $85,803.68 | $2124.78 | $101,989.44 | $16,181.76 | |
| OCT-only model | ||||||
| Bevacizumab | 96 | $68.85 | $6049.92 | $193.93 | $18,617.28 | $12,007.68 |
| Aflibercept | $1770.88 | $70004.48 | $2034.39 | $195,301.44 | $25,296.96 | |
DFE = dilated fundus examination; OCT = optical coherence tomography; VA = visual acuity.